Ranger Biotechnologies A/S: Financial statements 2016
CVR: 32280404
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
Ranger Biotechnologies A/S (CVR 32280404) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK 2,138,000 and a net result of DKK 1,520,000 compared with DKK -633,000 the year before. Equity in the 2016 report amounted to DKK 5,895,000. The solvency ratio was 41.2%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 2,138,000
- Profit/Loss
- DKK 1,520,000
- Equity
- DKK 5,895,000
- Total Assets
- DKK 14,304,000
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | 2.1M | 1.5M | 5.9M | 1 |
| 2015 | - | -733K | -633K | 4.4M | 1 |
| 2014 | - | -1.2M | -1.3M | 4.7M | 1 |
| 2013 | - | -699K | -1.1M | 6M | 1 |
| 2012 | - | -756K | -1.2M | 5.6M | - |
Official annual report
Find more companies like Ranger Biotechnologies A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
Ranger Biotechnologies A/S has published its annual report for 2015. Gross profit came to DKK -733,000, and the net result was DKK -633,000.
About Ranger Biotechnologies A/S
Ranger Biotechnologies A/S is a Danish company of the type Aktieselskab based in Odense SØ, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MIRRX THERAPEUTICS A/S and MIRX THERAPEUTICS A/S. The management consists of Hans Thorleif Møller. The board consists of Christina Møller Udesen (chair), Hans Thorleif Møller, Kasper Tvede Larsen and Søren Tvede Larsen. The company is owned by QUERDENKER ApS and Outlate Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -409,444 and a net result of DKK -843,419 compared with DKK -1,138,092 the year before. Equity in the 2025 report amounted to DKK 711,273.